The inherited condition behind many multiple and recurrent BCCs
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Gorlin syndrome — also called basal cell nevus syndrome or nevoid basal cell carcinoma syndrome (NBCCS) — is a rare inherited condition that predisposes a person to develop many basal cell carcinomas (BCCs) over a lifetime, often starting in the teens or twenties and sometimes numbering in the dozens or hundreds. It also affects the jaw, the skeleton, and, less commonly, the developing brain and heart. Estimates of how common it is range from about 1 in 30,000 to 1 in 60,000 people.
Recognizing the syndrome matters because it changes how BCCs are managed: the goal shifts from treating one tumor aggressively to protecting skin and healthy tissue over decades. This article covers the main features, how it is inherited, why it drives so many BCCs, how it is diagnosed, and what it means for treatment — including an important caution about radiation.
Gorlin syndrome affects several body systems, and no two people have exactly the same combination. Features doctors look for include:
In a classic series of 105 affected people, basal cell carcinomas were present in the large majority of adults, jaw cysts in about three-quarters, and rib anomalies in roughly one-third — a reminder that the picture is variable, not uniform.
Gorlin syndrome is autosomal dominant: a single altered gene copy is enough to cause it, and a parent who carries it has a 50% chance of passing it to each child. About 20–30% of people with the syndrome have no affected relative — in them the gene change is de novo (new), arising around the time of conception, and they can still pass it to their own children.
Most cases (roughly 50–75% of those with a clinical diagnosis) are caused by loss-of-function changes in PTCH1, a gene on chromosome 9. A smaller number are due to changes in SUFU (associated with a higher medulloblastoma risk) or, rarely, PTCH2. Some people who clearly have the syndrome on clinical grounds have no identifiable gene change with current testing.
PTCH1 and SUFU are both brakes on the hedgehog signaling pathway, a system that guides tissue growth before birth and is normally switched off in adult skin. This is the same pathway targeted by the drugs used for advanced BCC.
In sporadic (non-inherited) BCC, both copies of a hedgehog-pathway gene have to be knocked out by chance in a single skin cell before a tumor starts — an uncommon event, which is why most people who get BCCs get only one or a few.
In Gorlin syndrome, every skin cell already starts with one faulty copy of PTCH1. Only one more "hit" — from ultraviolet light, radiation, or ordinary cell division — is needed to release the brake on hedgehog signaling in that cell. Across a lifetime and billions of skin cells, that second hit happens again and again, so new BCCs keep forming, including on skin that rarely sees the sun.
This also explains two practical points: sun protection matters even more than usual, because UV is a major source of the second hit; and ionizing radiation is a potent trigger, which is central to the treatment cautions below.
Diagnosis rests on a published set of major and minor criteria (from an international consensus panel), combined where possible with genetic testing. A clinical diagnosis is generally made when someone has two major criteria, or one major plus two minor criteria; identifying a PTCH1 or SUFU change confirms it.
Work-up often includes a panoramic jaw X-ray (orthopantomogram), skull imaging, a spine and rib series, a thorough skin exam, and, for children, close developmental and neurologic follow-up.
Genetic counseling is recommended for anyone with a confirmed or suspected diagnosis. A counselor can explain testing options, coordinate testing of relatives, and discuss reproductive choices. Because the syndrome can appear in childhood, testing of at-risk children is often considered so surveillance can begin early.
The strategy is lifelong tissue preservation, not just tumor removal:
People with Gorlin syndrome are unusually sensitive to ionizing radiation. Radiation therapy delivered to the skin — or to deeper structures, with skin in the beam's path — can trigger large numbers of new BCCs within the treated field, sometimes appearing only 6 months to 3 years later. Historically, children treated with craniospinal radiation for medulloblastoma have developed dense clusters of BCCs across the back.
Because of this, radiotherapy for a BCC is generally avoided in Gorlin syndrome whenever an alternative exists, and diagnostic radiation (such as repeated CT scans) is kept to what is clinically necessary. When radiation is genuinely needed, the risks and benefits are weighed carefully by the team, and techniques that spare skin are preferred.
Tell every clinician you see — dermatologist, dentist, oncologist, radiologist — that you have Gorlin syndrome, so imaging and treatment decisions account for it.
Gorlin syndrome is the inherited condition behind many cases of multiple and recurrent BCCs. It comes from a change in a hedgehog-pathway gene — usually PTCH1 — that leaves every skin cell one step closer to forming a tumor, and it also affects the jaw and skeleton. Care is a long game: frequent skin checks, tissue-sparing treatment of individual BCCs, selective use of hedgehog pathway inhibitors, meticulous sun protection, and caution with radiation.
If you or a close relative has had unusually early or numerous BCCs, ask a dermatologist whether an evaluation for Gorlin syndrome and a referral for genetic counseling make sense.
Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified dermatologist, geneticist, or genetic counselor about diagnosis, testing, and management of Gorlin syndrome.
Chat with our AI guide for information about Gorlin syndrome and basal cell carcinoma
Chat with the Navigator